Saynor Seeks To Take Sandoz Back To Basics
Should Be Proud To Be A Generics Company
In an exclusive interview with Generics Bulletin, Sandoz’ CEO Richard Saynor explains how he wants the Novartis division to focus on the industry basics of being first-to-market with cost-competitive generics and biosimilars.
